rethinkTHC Search
Menu
Study breakdown

Higher-potency synthetic cannabinoids developed less tolerance than THC in monkeys

Animal StudyPreliminary evidence
The takeaway

After 14 days of daily THC, monkeys lost 9.2-fold sensitivity to THC but only 3.6-fold to the higher-efficacy agonist CP-55,940, suggesting synthetic cannabinoids may resist tolerance more than THC.

Read this if you want to understand why synthetic cannabinoids may carry different addiction risks than natural cannabis.

THC: 9.2-fold tolerance. Synthetics: only 3.6-5.6-fold

What the researchers found

Rhesus monkeys trained to discriminate THC were given daily THC (1 mg/kg) for 3 or 14 days. After 3 days, tolerance developed to THC (3-fold sensitivity loss) but not to higher-efficacy agonists CP-55,940, JWH-018, or JWH-073.

After 14 days, tolerance extended to all compounds but was inversely related to agonist efficacy: THC sensitivity decreased 9.2-fold, while CP-55,940 decreased only 3.6-fold, JWH-018 decreased 4.3-fold, and JWH-073 decreased 5.6-fold.

This inverse relationship between agonist efficacy and tolerance development followed predictions from receptor theory: low-efficacy agonists (like THC) need more receptors to produce their effect, so receptor downregulation has a greater impact on them.

Why it matters

This explained why synthetic cannabinoid users may escalate doses differently than cannabis users. If synthetics resist tolerance, users might not need to increase doses as much, but the higher baseline potency plus sustained efficacy could increase dependence liability.

The numbers in context

14-day tolerance: THC 9.2-fold, CP-55,940 3.6-fold, JWH-018 4.3-fold, JWH-073 5.6-fold. 3-day tolerance: THC 3-fold, others no change.

How the study worked

Drug discrimination in rhesus monkeys (n=4) discriminating THC (0.1 mg/kg i.v.). Dose-response curves for THC, CP-55,940, JWH-018, and JWH-073 measured before and after 3 and 14 days of daily THC treatment (1 mg/kg s.c.).

What this study cannot tell us

Small number of monkeys (4). Cross-tolerance rather than direct tolerance was measured for the synthetics. Only discriminative stimulus effects were assessed; other behavioral effects may show different tolerance patterns.

How to read the evidence

Primate pharmacology study with rigorous receptor theory framework. Small sample but highly controlled conditions.

When this study was published

Published in 2012. The proliferation of synthetic cannabinoids has made understanding their pharmacological differences from THC increasingly important.

The bigger picture

Understanding efficacy-tolerance relationships helps predict which cannabinoids carry greater dependence risk. Higher-efficacy synthetics that resist tolerance more than THC could produce more sustained receptor activation, potentially leading to different withdrawal profiles.

Questions still open

  • Does resistance to tolerance make synthetic cannabinoids more addictive? Would cross-tolerance patterns predict which synthetics are most dangerous? Can efficacy-based predictions guide scheduling of new synthetic cannabinoids?

Common questions

Why do synthetic cannabinoids resist tolerance?
THC is a partial agonist (relatively low efficacy), while many synthetics are full agonists (high efficacy). When the brain reduces receptor numbers in response to chronic use, low-efficacy drugs are affected more because they need more receptors to work.
Does this make synthetics more dangerous?
Potentially. Less tolerance development means sustained receptor activation over time, which could lead to greater physical dependence. Combined with higher potency and shorter duration (requiring more frequent dosing), synthetics may carry elevated addiction risk.

Read the original research

Apparent inverse relationship between cannabinoid agonist efficacy and tolerance/cross-tolerance produced by Δ⁹-tetrahydrocannabinol treatment in rhesus monkeys.

The Journal of pharmacology and experimental therapeutics, 342(3), 843-9

Citation

Hruba, Lenka; Ginsburg, Brett C; McMahon, Lance R. (2012). Apparent inverse relationship between cannabinoid agonist efficacy and tolerance/cross-tolerance produced by Δ⁹-tetrahydrocannabinol treatment in rhesus monkeys.. The Journal of pharmacology and experimental therapeutics, 342(3), 843-9. https://doi.org/10.1124/jpet.112.196444

Explore the wider topic